Ecnoglutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A cAMP-biased GLP-1 receptor agonist marketed for weight loss and glucose control in type 2 diabetes. Human data are unusually strong for a peptide, roughly 15% weight loss at 48 weeks plus A1c and liver fat gains, but nearly all from Chinese trials, unconfirmed elsewhere. Risks include GLP-1 nausea, an unresolved theoretical thyroid tumor signal, and a new mechanism with no long-term safety record. Not an approved drug in the US; supply warrants caution.
Read Full recordStudied uses & evidence
Studied uses(6)
Exceptional weight loss (15.4% at 48 weeks, no plateau observed)
HighPeer-reviewed phase 3 RCT showed 13.2% loss at 40 weeks; 48-week 15.4% figure is company-reported.
92.8% of patients achieved clinically meaningful >=5% weight loss
HighRandomized trial confirmed high response rates; the 92.8% figure comes from company reporting.
Superior HbA1c reduction in T2D (up to 2.43% from baseline at 1.2 mg)
HighTwo randomized phase 3 trials showed greater HbA1c reduction than placebo and dulaglutide.
Evidence limits
- Evidence Level
- Strong Evidence (Phase 3, Approved in China)
Ecnoglutide has completed Phase 3 trials for both obesity (SLIMMER) and type 2 diabetes (EECOH-1) with results published in top-tier journals (The Lancet Diabetes & Endocrinology, Nature Communications). It has been approved by China's NMPA for chronic weight management. Phase 3 data demonstrated 15.4% weight loss at 48 weeks and 2.43% HbA1c reduction at 24 weeks. All trials were conducted in Chinese populations; global Phase 3 data are not yet available.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events (GLP-1 class effects)
HighLimited data outside Chinese populations
HighThyroid C-cell tumor risk (GLP-1 class warning)
TheoreticalNovel biased mechanism with limited long-term safety data
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.